CanJPsychiatry 2012;57(5):292-299 Objective: To determine whether implementation of a metabolic monitoring training program (MMTP) in an urban community-based setting improved monitoring in children treated with second-generation antipsychotics (SGAs) and changed prescription rates of SGAs to children. was performed to collect the following data: age, sex, foster care, immigrant status, Axis I diagnosis, and medications. In SGA-treated children, anthropometric measurements and blood work completed at baseline and 3, 6, and 12 months were also collected.
Abbreviations

Clinical Implications
• Implementation of the MMTP in a community setting was associated with a significant improvement in metabolic monitoring of SGA-treated children.
• A significant decrease in SGA prescriptions to children treated in a community-based setting was observed after implementation of the MMTP.
Limitations
• This was a retrospective cross-sectional study with no control group.
• Nonpharmacological treatments were not consistently recorded in the patients' charts.
• We were unable to ascertain why implementation of the MMTP resulted in a larger increase in monitoring at baseline than at the other time points. Further, prescription changes during this time period are observational data, and we are unable to determine direct causation with MMTP implementation.
S econd-generation antipsychotic prescriptions are on the rise in children, [1] [2] [3] and these medications can result in metabolic side effects, including hypertension, impaired glucose tolerance, dyslipidemia, and MetS. [3] [4] [5] If left untreated, these side effects may lead to serious cardiovascular complications and increased morbidity in adulthood. [6] [7] [8] While the risk of these complications highlights the importance of regular screening in SGA-treated patients, previous work has demonstrated variable monitoring rates. [9] [10] [11] [12] [13] [14] [15] [16] In 2004, a joint consensus statement from the ADA, the American Psychiatric Association, the American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity proposed a metabolic monitoring protocol for SGA-treated adults that involves regular anthropometric measurements and blood work, including fasting glucose and lipid profile. 17 Following publication of these guidelines, Morrato et al 9 documented an improvement in metabolic monitoring, ranging from 1.2% to 7.2%, in SGA-treated adults.
In Canada, there are very limited data available describing uptake of metabolic monitoring in children because, until very recently, no national clinical practice guidelines were available. We have previously published rates of monitoring in SGA-treated inpatients to be as low as 32% in the child and adolescent psychiatric inpatient unit in our hospital. 4 As a result of these findings, we developed an MMTP and implemented it in our hospital in January 2008. Through recent evaluation of this program, we observed that monitoring rates had increased dramatically within our inpatient unit since the MMTP implementation. Specifically, height measurements increased from 39% to 89%, fasting glucose increased from 34% to 89%, and measurement of a lipid profile increased from 32% to 89%. 18 Notably, Canadian clinical practice guidelines for monitoring SGAtreated children were very recently developed and endorsed by both the Canadian Academy of Child and Adolescent Psychiatry and the Canadian Pediatric Society. 19 These guidelines incorporate our copyrighted MMT 20 as a simplified and practical single screening and monitoring tool for use in the clinical setting.
After the success of the MMTP in our inpatient units, the medical director of Vancouver Coastal Health communitybased mental health teams requested that this training program be implemented, given known low monitoring rates. The objectives of our study were to determine whether implementation of an MMTP in an urban communitybased mental health setting improved monitoring in SGA-oeuvre du PFSM, 38,3 % avaient une copie du PFSM dans leur dossier sur papier. La surveillance métabolique a augmenté de jusqu'à 40 % au départ (P < 0,01), de 20 % à 3 mois (P < 0,01) et à 6 mois (P < 0,01), et de 18 % à 12 mois après la mise en oeuvre du PFSM.
Conclusions : La mise en oeuvre d'un PFSM était associée à des taux de surveillance significativement améliorés des paramètres anthropométriques et d'analyses sanguines au départ et aux suivis de 3 et 6 mois, avec une tendance à l'amélioration à 12 mois, chez des enfants traités par ADG et soignés dans des cliniques de santé mentale communautaires urbaines. En outre, une diminution de 56 % des prescriptions d'ADG a été observée après la mise en oeuvre du PFSM dans cette population. treated children, and changed prescription rates of SGAs to children.
Method
Study Design
This study was reviewed and approved by the Children's and Women's Research Ethics Boards, the University of British Columbia Research Ethics Boards, and the Vancouver Coastal Health Research Ethics Board. We conducted a retrospective chart review of children (aged 18 years or younger) presenting to Vancouver Coastal Health CYMHTs between September 1, 2007, and April 30, 2010.
The CYMHTs are community-based mental health teams that provide psychiatric care and counselling to children (aged 18 years and younger) and their families within the Vancouver city limits. Seven CYMHTs were included in this study. Each team is unique and is staffed by at least one child and adolescent psychiatrist and any combination of the following health care professionals: pediatricians, nurses, mental health clinicians, and psychologists.
The MMTP
The MMTP has been described in detail elsewhere 21 and includes the MMT, a physician handbook for metabolic monitoring and training workshops for all staff. The MMT is available online. 20 In short, the MMT was developed based on consultation with several pediatric and psychiatric subspecialists, a thorough review of the literature, 3 and available adult guidelines. It provides recommendations for completing anthropometric measurements (including weight, height, WC, and blood pressure) and for the monitoring of various blood work parameters (including fasting glucose, insulin, total cholesterol, LDL-C, HDL-C, TGs, ALT, AST, and prolactin) at several time points throughout the first year of SGA treatment (including at baseline, and at 3, 6, 9, and 12 months). Before implementation of the MMTP, physicians from BC Children's Hospital travelled to the CYMHTs and explained the risks of SGA use in children to staff. The MMTP also included a comprehensive handbook for physicians 22 that includes information about FDA and Health Canadaapproved indications for SGAs and about metabolic side effects and monitoring. In partnership with Vancouver Coastal Health, the MMTP was implemented within the CYMHTs on January 1, 2009, and included the physician handbook, MMT, and an educational in-service for the CYMHT staff about the use of the MMT and training on standardized measurement techniques in children. For each team, the child and adolescent psychiatrist was responsible for ordering blood work; however, owing to dissimilar staffing complements within the CYMHTs, 21 a project coordinator worked with each team individually to determine which staff would assume responsibility for completing anthropometric measurements.
Data Collection
A list of the children seen at the CYMHTs from September 1, 2007, to April 30, 2010, was generated by the Vancouver Coastal Health Child and Youth Mental Health Manager. The Vancouver Coastal Health paper charts and electronic records were used to collect the following information about each subject: date of birth, date of assessment at the CYMHT, sex, ethnicity, foster care, immigrant status, medication information (including name of medication, dose, date of initiation, and duration), diagnosis, and completion of anthropometric measurements (including height, weight, WC, and blood pressure) and blood work (including fasting glucose, insulin, total cholesterol, LDL-C, HDL-C, TGs, ALT, AST, and prolactin) at each monitoring time point.
Analysis
Data were analyzed using SPSS software, version 18.0 (SPSS Inc, Chicago, IL). To account for multiple comparisons, a P level of less than 0.01 was used to define statistical significance. Chi-square tests were conducted to describe baseline characteristics of the population, including sex, immigrant status, and foster care, Axis I diagnoses, and medications. A chi-square test was also conducted to assess the difference between the rate of SGA prescriptions in the 16 months before the MMTP was implemented (September 1, 2007, to December 31, 2008) and in the 16 months after the MMTP was implemented (January 1, 2009, to April 30, 2010).
SGA-Treated Subsample Analysis
SGA-treated subjects were included in either the pre-or the post-MMTP group based on whether their care took place before or after the MMTP was implemented. Descriptive analyses were used to compare the baseline demographics of the SGA-treated children and to assess monitoring rates for each variable before and after MMTP implementation. Pearson chi-square tests were conducted to compare monitoring rates for each variable and concomitant medication prescriptions before and after MMTP implementation.
Results
Study Subjects
There were 1114 children seen at the CYMHTs from September 1, 2007, to December 31, 2008 (pre-MMTP implementation period), and 1262 children seen from January 1, 2009, to April 30, 2010 (post-MMTP implementation period). The baseline characteristics of the children seen during these 2 time periods are presented in Table 1 . In the total sample of all study subjects (mean age 11.8 years, SD 4.81; range 1.86-18.34 years), there were no differences between the pre-and post-MMTP groups in the percentages of children that were male, in foster care, having new immigrant status, or with each of the Axis I diagnoses.
SGA-Treated Children
A subgroup composed of the SGA-treated children (mean age 14.5 years, SD 3.71; range 5.17-18.34 years) was analyzed separately. The baseline demographics of this group are presented in Table 2 . In this subsample, there were more males and more children in foster care assessed during the pre-MMTP time period than during the post-MMTP time period. Although there were no observed changes in the prevalence rates of any of the Axis I diagnoses in the total sample of children seen at the CYMHTs, there was a lower proportion of children diagnosed with ADHD or a relational disorder in the post-MMTP implementation time period within the SGA-treated subpopulation. In addition, there was a higher prevalence of depression and psychosis diagnoses documented in the SGA-treated subgroup in the post-MMTP implementation time period.
Overall, differences in the breakdown of which SGAs were prescribed pre-and post-MMTP were observed that did not reach statistical significance (P = 0.02). Among the children treated with SGAs at each time point, quetiapine prescriptions increased from 22.1% pre-MMTP to 34.6% post-MMTP, whereas risperidone prescriptions decreased from 48.8% to 40.7%. Olanzapine prescriptions did not significantly change, accounting for 3.5% of prescriptions pre-MMTP and 3.7% of prescriptions post-MMTP. Of interest, 25.6% of SGA-treated children pre-MMTP were treated with 2 SGAs, compared with 20.0% of SGA-treated children post-MMTP implementation.
Uptake of MMTP
Among the SGA-treated children seen at the CYMHTs after the implementation of the MMTP, 38.3% had a copy of the MMT in their paper chart. The rate of completion for each of the metabolic parameters recommended on the MMT at baseline and at 3, 6, and 12 months are presented in Table  3 . Of note, the monitoring of each of the anthropometric measures and blood work parameters increased significantly in SGA-treated children at baseline and the 3-and 6-month time points post-MMTP implementation, compared with pre-MMTP implementation. There was a trend for improved monitoring of all parameters at the 12-month time point; however, these differences did not reach statistical significance.
Medication Changes After MMTP Implementation
The breakdown of medications prescribed overall at the CYMHTs before and after implementation of the MMTP is presented in Table 4a . The proportion of children who were SGA-treated was much higher pre-MMTP than post-MMTP. Specifically, the prevalence rate of SGA prescriptions was 15.4% (172/1114) during the pre-MMTP implementation and 6.4% (81/1262) during the post-MMTP implementation (P < 0.001) time period.
The breakdown of medications prescribed to the SGAtreated children seen at the CYMHTs before and after implementation of the MMTP is presented in Table 4b . In this subsample of SGA-treated children, prescriptions of anxiolytics and antidepressants were higher in SGA-treated children seen post-MMTP implementation; in contrast, prescriptions of psychostimulants, atomoxetine, and mood stabilizers were higher in SGA-treated children assessed pre-MMTP implementation.
Discussion
To our knowledge, this is the first study to demonstrate that implementation of an MMTP in a community mental health setting is associated with a significant improvement in monitoring in SGA-treated children. In the first 16 months after MMTP implementation, monitoring rates increased by up to 40% at baseline, up to 20% at 3 and 6 months, and up to 18% at the 12-month time point. While some of the changes in monitoring at the later time points did not reach statistical significance, the overall observed increase of 18% at the 12-month time point is of clinical importance. Further, at baseline, the proportion of children with their weight and height measured increased by 34% and 30%, respectively. This is clinically relevant, given that both of these parameters are necessary for calculating the BMI. In addition to BMI, WC is an important measure of adiposity, and we found that the prevalence of WC measurement at baseline increased by nearly 10-fold. This is a key finding given that WC has previously been shown to be a sensitive method to predict risk for MetS in this population. 18 Moreover, abdominal adiposity is associated with insulin resistance and is a serious risk factor for CVD 6, [23] [24] [25] and it is, therefore, important that monitoring of this parameter be encouraged in this vulnerable population.
Our study also found significant improvements in monitoring of the parameters used to assess the 4 other components of the MetS (blood pressure, fasting glucose, TGs, and HDL-C). Improving the ability to assess these a Differences between pre-and post-MMTP were significant for all anthropometric measurements and blood work parameters (P < 0.01).
b Differences between pre-and post-MMTP did not reach statistical significance for these parameters.
c Our MMTP recommends prolactin measurements only at baseline and 12-month time points.
components is clinically important, given that the rate of MetS in SGA-treated patients has been reported to be as high as 43%. 26 Specifically, in our study, we found a 3-fold increase in monitoring of blood pressure and fasting glucose, and a 4-fold increase in monitoring of TGs and HDL-C at baseline.
While these improvements in monitoring are encouraging, there is still a substantial proportion of this population that is not receiving metabolic monitoring. Therefore, it is crucial that innovative strategies addressing barriers to metabolic monitoring uptake be developed and evaluated so that monitoring continues to improve to mitigate future cardiovascular complications that may result from untreated MetS or its components. 6 As well, although an improvement was seen at each time point regarding pre-MMTP rates, in the post-MMTP group, monitoring rates were greater at baseline than at the other time points. This trend could be due to numerous reasons, including:
1. needle phobia after baseline blood work resulting in children not completing blood work at other time points, 2. physicians not remembering to perform all recommended measures and blood work tests at subsequent time points, or 3. physicians not documenting these measures and (or) laboratory tests performed in the chart.
It will be important to re-evaluate the use of the MMTP to assess how monitoring at these later time points can be improved.
Even with our concerns about lower monitoring rates at the later time points, the increase in metabolic monitoring seen in response to implementation of our MMTP is an improvement on previous findings. Morrato et al 16 found that glucose monitoring increased by 19% and lipid monitoring increased by 10% in SGA-treated children after the consensus guidelines authored by the ADA et al 17 were published. Morrato et al 9 also evaluated the uptake of these consensus guidelines in the adult population and found that baseline glucose monitoring increased by 15%; however, these results varied between different groups of SGA users. In another study in SGA-treated adults, 10 implementation of a metabolic monitoring protocol was evaluated through surveying of psychiatrists and found that 63% of psychiatrists reported adherence to the protocol; however, on careful review, it was noted that only 5% followed the protocol. It is important to note that one adult study 12 did show higher monitoring rates than we observed. Specifically, this study 12 found that lipid-monitoring rates increased to 83%, glucose monitoring to 65%, and WC to 43%; however, this study was conducted in a unique setting in that subjects were inmates of a correctional centre. 12 In our paper, we also observed that SGA prescription rates decreased by 58% in the time period following implementation of the MMTP in the community setting. We did not find any other studies that reported changes in overall SGA prescriptions to children after implementation of a metabolic monitoring protocol; however, one study 11 did report switching of SGA medication from those with more FDA warnings (olanzapine and clozapine) to one with fewer FDA warnings (aripiprazole) in the total population of SGA users after a warning was issued about metabolic side effects. In our study, we also observed an increase in quetiapine prescriptions and a slight decrease in risperidone prescriptions in the post-MMTP implementation time period. This observation is consistent with British Columbia prescription data indicating that quetiapine use is on the rise, provincially, and is likely independent from MMTP implementation. 27 Along with the marked decline in SGA prescriptions observed in our population after MMTP implementation, we observed an overall increase in prescriptions of antidepressants at the CYMHTs. Walter et al 28 recently surveyed child psychiatrists about the impact of metabolic side effect monitoring on prescription patterns and found that 62% of psychiatrists reported that they reduced their SGA prescriptions. Unlike the increase in antidepressants observed in our study, psychiatrists surveyed by Walter et al 28 reported increasing use of mood stabilizers. As well, we did observe a change in the SGA-treated population demographics. Specifically, after implementation of the MMTP, the percentage of SGA-treated children living in foster care decreased to match the percentage of children living in foster care in the total CYMHT population. Further, although we observed no significant changes in Axis I diagnoses in the total CYMHT population, children with ADHD or relational disorders were prescribed SGAs less often after MMTP implementation. In addition, children with psychosis or depression were more likely to be treated with SGAs after our MMTP was implemented. The reasons for these changes in prescribing practices are speculative at this point, and additional research is required to evaluate comorbid conditions in this vulnerable population.
Design Limitations
The main limitation of our study is that there was no control group; therefore, we could not control for independent external variables that may have influenced changes in prescribing or monitoring observed before and after MMTP implementation. Because of the retrospective crosssectional design of our study, we relied on the accuracy of the information in the patient charts and electronic records for data collection. That said, because we were able to review both the paper and electronic medical records and speak to CYMHT staff during data collection, we were likely able to gather all monitoring information for each child, regardless of where the information was recorded. Even with these multiple means of obtaining data, nonpharmacological treatments used at the CYMHTs were outside the scope of this study. As well, we were not able to establish why monitoring rates were lower at the 3-, 6-, and 12-month time points, compared with baseline, following MMTP implementation. Further, our paper reports on monitoring rates recorded in the paper chart and electronic records, and therefore, we were not able to ascertain whether children without recorded monitoring had not had blood work ordered by the physician or had declined monitoring after being provided with a blood work requisition by their physician. Additionally, while we were able to document a decrease in SGA prescriptions in children associated with MMTP implementation, we were unable to evaluate the role of other external variables that may have influenced rates of SGA-prescriptions. Finally, it was out of the scope of our study to evaluate the implications of this significant change in prescribing practices.
Conclusions
Implementation of an MMTP was associated with improved monitoring rates of all anthropometric and blood work parameters at the baseline and the 3-, 6-, and 12-month time points in SGA-treated children cared for in urban community-based mental health clinics. In addition, we observed a 56% decrease in SGA prescriptions in this population following implementation of the MMTP. Given the high prevalence of MetS and its components in SGAtreated children, 18 improved monitoring may lead to early detection and treatment of complications, and ultimately reduce the risk of CVD and diabetes in this high-risk population.
